Key Takeaways TEM expands its partnership with Northwestern Medicine, integrating its AI tool David into the EHR. TEM's AI assistant automates clinical summaries, note-taking, and treatment planning to aid clinicians. The collaboration aims to enhance workflows, cut administrative tasks, and improve patient outcomes. Tempus AI, Inc. (TEM) has expanded its longstanding collaboration with Northwestern Medicine, making it the first health system to integrate David, Tempus’ generative artificial intelligence (A ...

MESA, ARIZONA / ACCESS Newswire / October 10, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging leader in artificial intelligence-powered preventive health technologies, today highlighted the essential role of medical expertise, certified imaging data, and regulatory standards in developing trustworthy AI healthcare solutions. The company stated that while artificial intelligence has dramatically accelerated the pace of medical research, the foundation of any credible innovation still depen ...

Core Viewpoint - ZimVie Inc. has received approval from its stockholders for the acquisition by an affiliate of ARCHIMED, with the merger expected to close on October 20, 2025, pending all conditions being met [1][2]. Company Overview: ZimVie - ZimVie is a global leader in the dental implant market, focusing on developing, manufacturing, and delivering a wide range of products for dental tooth replacement and restoration [3]. - The company aims to enhance smiles, function, and confidence through its comprehensive solutions, which include dental implants, biomaterials, and digital workflow solutions [3]. - ZimVie operates from its headquarters in Palm Beach Gardens, Florida, and has additional facilities worldwide [3]. Company Overview: ARCHIMED - ARCHIMED is a prominent investment firm with a focus on healthcare industries, operating in Europe, North America, and Asia [4]. - The firm combines operational, medical, scientific, and financial expertise to act as both a strategic and financial partner for healthcare businesses [4]. - ARCHIMED manages €8 billion across various funds and emphasizes impact investing through its EURÊKA Foundation [4].

9k+ Digital Media Outlets 270k+ Journalists Opted In Media: Investors: Fallon McLoughlin Adam Reiffe Director, Public Relations Vice President, Investor Relations 201.258.0361 201.847.6927        [email protected] [email protected]     SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD ...

Core Insights - TELA Bio, Inc. has appointed Dr. Betty Jo Rocchio to its Board of Directors, while Lisa Colleran has stepped down after five years of service [1][3][4] Group 1: Appointment of Dr. Rocchio - Dr. Rocchio is a nationally recognized healthcare leader with extensive experience in clinical excellence and supply-chain transformation [2][5] - Currently, she serves as Executive Vice President and Chief Nurse Executive at Advocate Health, overseeing over 42,000 nurses [2][4] - Dr. Rocchio expressed her commitment to aligning clinical excellence with financial sustainability at TELA Bio [3][4] Group 2: Departure of Lisa Colleran - Lisa Colleran has resigned from the Board after five years, contributing significantly to TELA Bio's strategy and commercial growth [3][4] - Her leadership experience includes roles as CEO of IC Surgical and former CEO of LifeCell Corporation [3][4] Group 3: Company Overview - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation of the patient's anatomy [7] - The company aims to provide advanced, cost-effective solutions that enhance patient outcomes while minimizing the use of permanent synthetic materials [7]

Core Points - Haemonetics Corporation plans to release its second quarter fiscal year 2026 financial results on November 6, 2025, at 6:00 am ET [1] - A conference call for investors and analysts will take place on the same day at 8:00 am ET to discuss the results [1] Financial Results Announcement - The financial results will be published on November 6, 2025, at 6:00 am ET [1] - The conference call will provide an opportunity for discussion and Q&A regarding the financial results [1] Access Information - Participants can access the call via teleconference after completing registration, which provides a dial-in number and personalized PIN [2] - A live webcast of the call will be available on Haemonetics' investor relations website [2] - A replay of the conference call and webcast will be accessible for one year starting from November 6, 2025, at 11:00 am ET [2] Company Overview - Haemonetics is a global medical technology company focused on enhancing healthcare quality, effectiveness, and efficiency [3] - The company offers innovative solutions for hospital technologies, plasma collection, and blood component collection [3]

Core Viewpoint - Resmed plans to release its financial and operational results for Q1 of fiscal year 2026 on October 30, 2025, after market close, followed by a management webcast to discuss the results and other relevant information [1]. Group 1: Earnings Release Details - The earnings release will occur on October 30, 2025, after the New York Stock Exchange closes [1]. - A webcast will be hosted by Resmed management to discuss the results and other forward-looking information [1]. - A replay of the earnings webcast will be available on Resmed's investor relations website approximately two hours after the live event [2]. Group 2: Company Overview - Resmed is dedicated to creating innovative health technologies aimed at improving the quality of life for individuals in 140 countries [2]. - The company focuses on AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare [2]. - Resmed envisions a future where individuals can achieve better sleep and breathing through personalized care delivered at home [2].

Core Points - Coloplast's interim CEO Lars Rasmussen will not seek re-election to the Board at the upcoming Annual General Meeting on December 4, 2025 [1] - Lars Rasmussen has served Coloplast for nearly four decades, including 10 years as CEO and 7 years as Chair of the Board, significantly contributing to its transformation into a leading global MedTech company [2][5] - The company is entering a new phase with the implementation of its Impact4 strategy, which aims to enhance customer focus and support the goal of helping 4 million people in the long term [4][7] Leadership Transition - Jette Nygaard-Andersen will continue as interim Chair of the Board, leading the company during this transition period [5] - Niels B. Christiansen is proposed as a new Board member, with expectations to become Chair by December 2026 [6][7] - The Board is focused on strong succession planning and continuity, with unanimous support for the announced leadership changes [8] Company Mission and Vision - Coloplast's mission is to make life easier for individuals with intimate healthcare needs, driven by a commitment to innovation and empathy [11] - The company operates in various business areas, including Ostomy Care, Continence Care, Voice and Respiratory Care, Wound and Tissue Repair, and Interventional Urology [11]

Core Points - Coloplast's interim CEO Lars Rasmussen will not stand for re-election at the upcoming Annual General Meeting on December 4, 2025 [1] - Lars Rasmussen has served Coloplast for nearly four decades, including 10 years as CEO and 7 years as Chair of the Board, significantly contributing to its transformation into a leading global MedTech company [2][5] - The company is entering a new phase with the implementation of its Impact4 strategy, which aims to help 4 million people with intimate healthcare needs [4][7] Company Leadership Changes - Jette Nygaard-Andersen will continue as interim Chair of the Board, leading the company during this transitional period [5] - Niels B. Christiansen is proposed as a new Board member, expected to become Chair by December 2026, bringing relevant experience from the hearing aids industry and a strong customer-focused leadership background [6][7] - The Board of Directors supports the leadership changes and the search for a new CEO is progressing as planned [8]

Core Insights - Medtronic's BrainSense™ Adaptive Deep Brain Stimulation (aDBS) has been recognized by TIME as one of the Best Inventions, marking a significant advancement in healthcare technology for Parkinson's disease patients [1][4]. Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [6]. - The company has been a pioneer in deep brain stimulation (DBS) therapy for over 30 years, serving more than 200,000 patients with movement disorders [5]. Product Innovation - The BrainSense™ aDBS system is the world's first closed-loop DBS system, which personalizes therapy based on real-time brain activity, reducing the need for manual adjustments by patients [2][4]. - Medtronic has spent over 20 years developing this sensing-enabled DBS system, integrating therapeutic brain-computer interface (BCI) technology into its offerings [4]. Clinical Validation - The pivotal ADAPT-PD study published in JAMA Neurology demonstrated the clinical effectiveness, long-term safety, and patient preference for the BrainSense™ aDBS system [4]. - More than 1,000 patients worldwide have already received the adaptive therapy since its approval by CE Mark and U.S. FDA earlier this year [4]. Industry Recognition - TIME's annual Best Inventions list highlights innovations that significantly impact daily life, with Medtronic's technology being recognized for its intentional innovation and responsiveness to patient needs [3][5].